Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape 2023 - ResearchAndMarkets.com

2023-04-17

临床3期

DUBLIN--(BUSINESS WIRE)--The "Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.

'Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape'

This reports provides a data-driven overview of the current and future competitive landscape in ITP therapeutics.

Key Highlights

There will be more than 1.6 million diagnosed prevalent cases of ITP in 2023 across 16 pharmaceutical markets.

There are four leading marketed innovator drugs for the treatment of ITP, majority of marketed products are thrombopoietin receptor agonist thrombopoietin receptor agonist.

R&D activity in ITP is significant, with nine products in Phase III development.

Novartis has sponsored the highest number of clinical trials (nine) in ITP over the past 10 years.

In deals involving ITP assets, licensing agreements are the most common type of deal globally.

New innovator drugs are expected to enter the ITP market only after the next two years.

Scope

The publisher's Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

Disease Landscape

Disease Overview

Epidemiology Overview

Treatment Overview

Marketed Products Assessment

Breakdown by Mechanism of Action, Molecule Type, Route of Administration

Product Profiles with Sales Forecast

Pricing and Reimbursement Assessment

Retail or Manufacturer Price of Products

Time to Pricing and Time to Reimbursement

Pipeline Assessment

Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration

Product Profiles with Sales Forecast

Late-to-mid-stage Pipeline Drugs

Phase Transition Success Rate and Likelihood of Approval

Clinical Trials Assessment

Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status

Enrolment Analytics, Site Analytics, Feasibility Analysis

Deals Landscape

Mergers, Acquisitions, and Strategic Alliances by Region

Overview of Recent Deals

Commercial Assessment

Key Market Players

Future Market Catalysts

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the ITP market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ITP market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Topics Covered:

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Overview by Mechanism of Action

4.3 Overview by Route of Administration

4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

5.1 Manufacturer Price

5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

6.1 Phase III Pipeline Drugs

6.2 Overview by Development Stage

6.3 Overview by Molecule Type

6.4 Overview by Mechanism of Action

6.5 Overview by Route of Administration

6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

7.1 Historical Overview

7.2 Overview by Phase

7.3 Overview by Status

7.4 Overview by Phase for Ongoing and Planned Trials

7.5 Trials with Virtual Components

7.6 Geographic Overview

7.7 Single-Country and Multinational Trials by Region

7.8 Top 20 Sponsors with Breakdown by Phase

7.9 Top 20 Sponsors with Breakdown by Status

7.10 Overview by Endpoint Status

7.11 Overview by Race and Ethnicity

7.12 Enrollment Data

7.13 Top 20 countries for Trial Sites

7.14 Top 20 Sites Globally

7.15 Feasibility Analysis - Geographic Overview

7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

8.1 Mergers, Acquisitions, and Strategic Alliances by Region

8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/rmu1tn

Source: GlobalData

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.